|
Patent landscape, scope, and claims: |
US Patent 4,997,841 Landscape: Scope and Claim Coverage for Indole-5-ethanesulphonamide Cephalic Pain Compounds
US Patent 4,997,841 claims a class of substituted indole-5-ethanesulphonamides defined by formula (I), specific named species within that genus, and downstream medical-use and composition claims directed to “cephalic pain” indications, including migraine and cluster headache. The estate is structurally built to support broad compound coverage (genus with variable substituents) plus narrower “fallback” species claims plus formulation and method-of-treatment claims that would typically be implicated by any marketed product containing one of the claimed active compounds (or salts/solvates) for the claimed headache disorders.
What compounds are covered by US Patent 4,997,841 formula (I) and how broad is the genus?
Core claim architecture
The patent’s independent claim is claim 1, which defines a compound of formula (I) with variable substituents R1-R4 plus coverage for pharmaceutically acceptable salts and solvates.
Claim 1 scope (genus definition)
- R1: hydrogen or C1–6 alkyl
- R2: hydrogen or C1–6 alkyl
- R3: hydrogen (fixed)
- R4: hydrogen or C1–3 alkyl
- plus salt/solvate coverage.
Practical breadth implications
- The genus is substituent-variable at three positions (R1, R2, R4).
- R3 is fixed as hydrogen, reducing structural variability versus a fully substituted template.
- R1 and R2 each allow 7 choices (H plus C1–6 alkyl), yielding a multiplication effect on genus size; R4 allows 4 choices (H plus C1–3 alkyl).
- Maximum combinatorial possibilities under the stated degree of freedom (ignoring constraints of the drawn substituent map in formula (I)) is 7 × 7 × 1 × 4 = 196 distinct substituent combinations. The actual number of chemically and stereochemically distinct compounds could be smaller depending on whether multiple substituents map to the same structural positions and whether the formula implies additional fixed ring substitutions beyond the excerpt.
Salt and solvate
Claim 1 also explicitly covers “a pharmaceutically acceptable salt or solvate thereof.” This is commercially meaningful because it captures alternative solid forms that can otherwise be designed around in a strict structural infringement analysis.
Interpretation emphasis for claim construction
- The claim is a “Markush-like” variable substituent genus rather than an openly-ended functional claim.
- In US practice, such genus claims are enforced based on whether an accused product’s structure falls within the literal variable definitions.
Which specific named drug species are explicitly claimed and how do they narrow design-around options?
Claims 6–10 list specific members of the genus, each described by a fully specified N-substitution pattern and piperidinyl substitution pattern, all in the context of the same indole-5-ethanesulphonamide scaffold.
Explicit species coverage
- Claim 6: N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide (and salts/solvates)
- Claim 7: N,N-Dimethyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide (and salts/solvates)
- Claim 8: N-Ethyl-3-(4-piperidinyl)-1H-indole-5-ethanesulphonamide (and salts/solvates)
- Claim 9: N-Methyl-3-(4-piperidinyl)-1H-indole-5-ethanesulphonamide (and salts/solvates)
- Claim 10: 3-(1-Methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide (and salts/solvates)
Competitive relevance
Because these are named species claims, a competitor cannot easily argue that it is “outside the genus” if its API matches one of the explicitly listed structures. The named species also provide litigation leverage if the accused compound’s mapping to formula variables (R1-R4) is contested; the patentee can assert direct coverage via the enumerated structures.
What pharmaceutical compositions and dosage forms are covered for cephalic pain?
Composition-of-formulation claim coverage
- Claim 11: A pharmaceutical composition for use in treatment of conditions associated with cephalic pain comprising:
- an effective amount of at least one compound of formula (I) (claim 1), or salt/solvate
- with one or more pharmaceutically acceptable carriers/excipients.
- Claim 12: Conditions are limited to:
- migraine
- cluster headache
- chronic paroxysmal hemicrania
- headache associated with vascular disorders
- Claim 13: Composition adapted for oral, parenteral or intranasal administration.
- Claim 14: Unit dosage form with 0.1 mg to 100 mg active ingredient.
- Claim 15: Combines claim 13 administration route with the unit dosage range.
How the formulation claim constrains competitors
This is not a formulation-by-manufacturing-steps patent. It is a composition-use claim that tracks route and dose range. Under typical US infringement analysis, an accused product that uses:
- the claimed active (or salt/solvate) and
- is marketed with one of the specified administration routes
- at a dosage falling in the stated unit range
- and for one of the claimed indications
would face direct exposure on the composition claims.
Dosage window risk
The 0.1–100 mg per unit dose range is broad enough to cover many small-molecule oral and intranasal presentations and multiple strength products. If a competitor uses a different per-unit dose outside the window, that can create an argument, but the genus and method-of-treatment claims can still drive exposure depending on the product label and dosing regimen.
What method-of-treatment claims are asserted for migraine and cluster headache?
Method claims
- Claim 16: Method of treating migraine, cluster headache, chronic paroxysmal hemicrania, or vascular headache by administering an effective amount of a claim-1 compound (or salt/solvate).
- Claim 17: Method treating the same condition set by administering a pharmaceutical composition of claim 11.
- Claim 18: Method treating the same condition set by administering a pharmaceutical composition of claim 13 (route-specific: oral/parenteral/intranasal).
Label-driven enforcement exposure
Method-of-use claims often translate into litigation leverage when a Paragraph IV ANDA filer or NDA/BLA label includes:
- an indication matching claim 16/17/18, and
- a route consistent with claim 13/18.
A competitor that seeks to avoid method claim coverage typically must diverge on:
- indication (label carve-out),
- route (e.g., not oral/parenteral/intranasal), or
- active ingredient structure (avoid literal genus/species).
Given the explicit list of headache disorders, label alignment risk is central.
How does the claim set allocate strength between broad compound coverage and narrower species fallbacks?
Two-layer protection
- Genus layer: claim 1 (compound formula variables + salt/solvate)
- Species fallbacks: claims 6–10 explicitly enumerated molecules
- Downstream exposure hooks:
- composition with carriers and dosage range (claims 11–15)
- method-of-treatment (claims 16–18)
Litigation leverage
- If an accused product sits close to the boundary of R1/R2/R4 variable definitions, the genus claim may be contested.
- If structure maps to any enumerated species, claim 6–10 provides a direct foothold.
- For commercial products, even if compound coverage is litigated, method and composition claims can still be pressed based on label and product configuration.
What patents typically sit adjacent to US 4,997,841 for this class, and what gaps could exist?
This section cannot be populated with specific adjacent patents without external bibliographic confirmation (continuation family members, related patents, or prosecution history) beyond what is provided in the prompt. With only the claim text, the landscape can only be characterized structurally, not enumerated by patent numbers or assignees.
Structural gap analysis based on claim scope provided
- The claims do not appear to require:
- a specific manufacturing process
- a specific polymorph/hydrate identity
- a pharmacokinetic parameter
- a specific device or delivery system beyond route categories
This tends to broaden infringement reach for generic and label-follow-on products using the same active form.
- The claims do not clearly include:
- blood level targets, receptor targets, or biomarker thresholds
So design-around via different dosing strategy may not eliminate infringement unless it removes literal compliance with the unit dosage range and/or label indication.
When does US Patent 4,997,841 lose enforceability (filing-date dependent), and what exclusivity timelines matter?
No filing date, priority date, maintenance status, or patent term adjustment data are included in the prompt. Without those, exact expiration and any terminal disclaimer effects cannot be stated. The only actionable takeaway from the claim set alone is that enforceability and any generic-entry risk depend on:
- the patent’s issued term and maintenance,
- whether the patent is still in force,
- and whether any subsequent patents (continuations, formulation patents, or method-of-use continuations) extend coverage.
What generic entry risks exist for products containing these indole-5-ethanesulphonamide structures?
AND A/BLA risk drivers from this claim set
A company faces high entry risk if it can be characterized as supplying:
- the claimed active (compound formula (I) or one of the enumerated species 6–10), in a pharmaceutically acceptable salt or solvate, and
- a marketed use matching migraine, cluster headache, chronic paroxysmal hemicrania, or vascular-associated headache, and
- a route matching oral, parenteral, or intranasal (for claims 13/18 and label alignment).
What design-arounds are plausible based on the claim language
- Change R1/R2/R4 substitution pattern to fall outside the variable definitions (risk depends on claim construction and whether literal exclusion succeeds).
- Use a different salt/solvate not covered only if it cannot be argued as “pharmaceutically acceptable” and the claim construction excludes it. The claim language is broad enough that most salts used clinically will be argued “pharmaceutically acceptable.”
- Avoid the labeled indications in the claimed set (often the most straightforward regulatory tactic but can be undermined if the product’s induced off-label use is relevant to method claims, depending on enforcement posture).
How does this patent compare with typical migraine/cluster headache small-molecule IP strategies?
Claim pattern is consistent with “active scaffold + indication use + formulation adapters.”
Many headache IP packages split protection across:
- compound/genus patents,
- method-of-treatment patents tied to migraine or cluster headache indications,
- formulation patents for route and dosage.
In this case, the package is compact: it includes genus/species, then immediately claims composition and method across the primary headache disorders named. That makes it unusually direct for a competitor: if the active and indication align, infringement exposure is immediate without requiring a specialized formulation novelty.
Key Takeaways
- US Patent 4,997,841 protects a genus of indole-5-ethanesulphonamides with variable R1/R2 (H or C1–6 alkyl), R3 fixed as H, and R4 (H or C1–3 alkyl), plus salts/solvates.
- It includes explicit compound species claims (claims 6–10) that materially reduce ability to design around by structural “near misses.”
- It adds composition-for-use claims covering migraine, cluster headache, chronic paroxysmal hemicrania, and vascular-associated headache, with route limitation (oral/parenteral/intranasal) and a unit dose range of 0.1–100 mg.
- It includes method-of-treatment claims that track the same indication set and administration routes, creating label-driven enforcement risk for any product using the claimed active.
FAQs
-
Do salts and solvates of the claimed indole-5-ethanesulphonamides fall within US 4,997,841 coverage?
Yes. Claim 1 and the species claims include “pharmaceutically acceptable salt or solvate thereof.”
-
Is the patent limited to oral dosing or also covers intranasal and parenteral administration?
Yes. Claims 13 and 18 expressly cover oral, parenteral, and intranasal routes.
-
What exact headache indications are covered by the composition and method claims?
Migraine, cluster headache, chronic paroxysmal hemicrania, and headache associated with vascular disorders (claims 12, 16–18).
-
What is the unit dosage range of active ingredient protected by the formulation claims?
Claims 14 and 15 specify 0.1 mg to 100 mg per unit dosage form.
-
If a competitor’s API matches one of the enumerated species (claims 6–10), can they rely on genus variability to avoid infringement?
No. A match to any enumerated structure creates direct coverage under the species claims, making genus-boundary arguments less relevant.
References
- US Patent 4,997,841 (claims as provided in prompt).
More… ↓
⤷ Start Trial
|
